Skip to main content

Advertisement

Table 2 Medications after enrollment

From: Deleterious role of hepatitis B virus infection in therapeutic response among patients with rheumatoid arthritis in a clinical practice setting: a case-control study

Medication CHB group (n = 32) Non-CHB group (n = 128) p valuea
Initial medications, n (%)
 GCs 23 (72) 89 (70) 0.817
   <5 mg/day 1 (3) 3 (2) 0.821
   ≥5, ≤10 mg/day 19 (59) 81 (63) 0.715
   >10, ≤20 mg/day 2 (6) 4 (3) 0.462
   >20 mg/day 1 (3) 1 (1) 0.357
 MTX 28 (87) 121 (95) 0.217
   ≤10 mg/week 21 (66) 79 (62) 0.715
  >10, ≤15 mg/week 6 (19) 40 (31) 0.217
   >15 mg/week 1 (3) 2 (2) 0.606
 LEF 5 (16) 107 (84) <0.001
 SSZ 14 (44) 2 (2) <0.001
 HCQ 24 (75) 14 (11) <0.001
 CysA 4 (13) 4 (3) 0.062
 Iguratimod 1 (3) 10 (8) 0.415
 Biologic agents 6 (19) 38 (30) 0.273
  Tocilizumab 4 (13) 30 (23) 0.234
  Yi Sai Pu 2 (6) 5 (4) 0.606
  Infliximab 0 (0) 3 (2) NA
Six-month cumulative dose of medicationsb (mg)
 GCs 900 (0–1406) 1069 (0–1556) 0.506
 MTX 260 (201–315) 288 (260–348) 0.024
 LEF 0 (0–0) 1800 (1500–3263) <0.001
 SSZ 0 (0–270,000) 0 (0–0) <0.001
 HCQ 54,000 (3000–72,000) 0 (0–0) <0.001
 CysAc 0 (0–19,515) 0 (0–4500) 0.020
 Iguratimodc 0 (0–2625) 0 (0–9000) 0.330
 Tocilizumabc 0 (0–1880) 0 (0–2400) 0.218
 Yi Sai Puc 0 (0–600) 0 (0–0) 0.606
 Infliximabc 0 (0–0) 0 (0–0) NA
One-year cumulative dose of medications (mg)
 GCs 1800 (0–2790) 1744 (0–2475) 0.418
 MTX 520 (413–650) 585 (520–715) 0.023
 LEF 0 (0–0) 3600 (2719–6600) <0.001
 SSZ 68,000 (0–536,000) 0 (0–0) <0.001
 HCQ 90,000 (3000–144,000) 0 (0–0) <0.001
 CysAc 0 (0–37,575) 0 (0–12,825) 0.016
 Iguratimodc 0 (0–5775) 0 (0–9000) 0.393
 Tocilizumabc 0 (0–1880) 0 (0–2800) 0.184
 Yi Sai Puc 0 (0–600) 0 (0–0) 0.606
 Infliximabc 0 (0–0) 0 (0–0) NA
  1. Data are presented as median (interquartile range (IQR)) or number (percentage (%)) unless stated otherwise
  2. CHB chronic hepatitis B virus (HBV) infection, CysA cyclosporin A, GC glucocorticosteroid, HCQ hydroxychloroquine, LEF leflunomide, MTX methotrexate, NA not applicable, SSZ sulfasalazine
  3. aCompared between the CHB group and the non-CHB group using conditional logistic regression analysis: bold p values are significant
  4. bWithin the initial 6 months after enrollment
  5. cData were analyzed as median (5th/95th percentile ranges) due to the small number of patients using these medications